Welcome to our dedicated page for Goodrx Holdings news (Ticker: GDRX), a resource for investors and traders seeking the latest updates and insights on Goodrx Holdings stock.
GoodRx Holdings, Inc. (NASDAQ: GDRX) is widely described as the leading platform for medication savings in the U.S., and its news flow reflects that role at the intersection of digital healthcare, pharmacy, and pharmaceutical manufacturers. Company announcements highlight new partnerships, product launches, and financial updates that shape how consumers, pharmacies, and manufacturers approach prescription affordability.
News about GoodRx often covers collaborations with major healthcare players. Examples include the RxSmartSaver program powered by GoodRx at national and regional retail pharmacies, which brings brand medication savings directly to the pharmacy counter, and an exclusive partnership with Surescripts that integrates GoodRx discounted cash prices into Script Corner, a patient experience product focused on prescription price transparency.
GoodRx also issues press releases on new consumer offerings and subscriptions. Recent updates describe GoodRx for Weight Loss, a telemedicine subscription for GLP-1 weight management treatment, and GoodRx for Hair Loss, a subscription program for men that combines virtual consultations, prescriptions for oral finasteride or oral minoxidil when appropriate, and discreet home delivery. Additional news highlights defined cash prices for medications such as Repatha, Ozempic, Wegovy, and the Wegovy pill at tens of thousands of pharmacies nationwide via GoodRx.
Investors and observers can also find earnings-related news, including quarterly financial results, guidance commentary, and participation in healthcare conferences. Together, these updates provide insight into GoodRx’s strategy across prescription transactions, subscriptions, pharma manufacturer solutions, and telehealth. For anyone tracking GDRX, this news page offers a focused view of how the company is evolving its platform, expanding partnerships, and addressing medication affordability across the U.S. healthcare system.
GoodRx (Nasdaq: GDRX) will release first quarter 2026 results after U.S. markets close on Wednesday, May 6, 2026.
Management will host a conference call and webcast on Thursday, May 7, 2026 at 5:00 a.m. PT (8:00 a.m. ET); materials and an archived webcast will be available on the investor relations website.
GoodRx (Nasdaq: GDRX) announced Wegovy® HD (semaglutide 7.2 mg) is available to eligible self-pay patients at a $399 per month price, with two- and three-month supplies at $798 and $1,197 respectively. GoodRx for Weight Loss offers eligibility assessment, provider visits, and prescription support nationwide.
The offering aims to expand access to FDA-approved GLP-1 dosing with upfront pricing and pharmacy fulfillment through GoodRx’s platform.
GoodRx (Nasdaq: GDRX) expanded access to Eli Lilly’s new oral GLP-1 Foundayo (orforglipron) and to Zepbound KwikPen. Eligible self-pay patients can access Foundayo starting at $149/month and Zepbound KwikPen starting at $299/month at more than 70,000 pharmacies nationwide. GoodRx said these offerings provide transparent cash pricing and nationwide pharmacy access, supporting direct-to-consumer launch models as insurance coverage for GLP-1 treatments remains inconsistent.
GoodRx reported a platform reach of nearly 25 million consumers and highlighted its role connecting manufacturers, pharmacies, clinicians, and patients.
GoodRx (Nasdaq: GDRX) and Viatris announced a collaboration to make 17 established brand medications more affordable in the U.S. Eligible commercially insured patients may pay $0–$4 on select Viatris drugs; cash prices can be discounted up to 85% off at > 70,000 pharmacies. Brands included: Lipitor, Celebrex, Viagra, and Norvasc. GoodRx cites nearly 25 million annual users and says the platform has helped save over $100 billion since 2011. The program aims to expand access and support adherence for established brands, including those navigating loss of exclusivity.
GoodRx (Nasdaq: GDRX) will enable self-insured employers to subsidize Eli Lilly’s Employer Connect price of $449 for Zepbound® (tirzepatide) KwikPen across all doses, applying employer contributions in real time at the pharmacy counter.
GoodRx Employer Direct integrates manufacturer discounted pricing, employer funding, and optional telemedicine to simplify prescribing, fulfillment, and reduce employee out-of-pocket costs while complementing—but not replacing—traditional health plans.
GoodRx (Nasdaq: GDRX) reported Q4 2025 revenue of $194.8M and full-year 2025 revenue of $796.9M. Full-year adjusted EBITDA was $270.5M with an adjusted EBITDA margin of 33.9%. Pharma Direct revenue grew 41% to $151.4M. Net income for 2025 was $30.4M. The company repurchased 48.9M shares for $217.4M and finished 2025 with $261.8M cash and $495.0M debt. Management provided FY2026 revenue guidance of $750M–$780M and Adjusted EBITDA above $230M. A conference call is scheduled for February 26, 2026.
GoodRx (Nasdaq: GDRX) launched GoodRx Employer Direct on February 24, 2026, offering employers targeted subsidies to lower employee out-of-pocket costs for high-impact brand medications, including GLP-1s like Wegovy. Employer Direct also offers branded telemedicine solutions that integrate clinical care, prescribing, and pharmacy fulfillment while complementing existing health plans.
The program began with initial employer partners, including Hy-Vee, and applies employer contributions at the pharmacy counter to reduce costs without altering core plan structures.
GoodRx (Nasdaq: GDRX) is a core integration partner for TrumpRx, powering pricing for leading brand medications at launch.
GoodRx will serve as the integrated pricing source for Pfizer for over 30 essential brand medications, offering savings up to 85% and averaging 50% on many primary care and select specialty treatments. GoodRx says its platform reduces operational lift for manufacturers and enables rapid deployment of discounted cash pricing nationally.
GoodRx (Nasdaq: GDRX) earned its 2026 HITRUST i1 Certification for its prescription savings platform hosted on Amazon Web Services. The certification validates controls for protecting sensitive healthcare data and risk management across data centers in California, Ohio, Oregon, and Virginia.
The award follows independent third-party testing and signals ongoing investment in cybersecurity and trust for a platform used by nearly 25 million consumers and over one million healthcare professionals annually.
GoodRx (Nasdaq: GDRX) will release its fourth quarter and full year 2025 results after U.S. markets close on Wednesday, February 25, 2026.
Management will host a conference call and webcast on Thursday, February 26, 2026 at 5:00 a.m. PT (8:00 a.m. ET). According to the company, materials and a live webcast will be available at https://investors.goodrx.com, and an archived webcast will be posted for at least 30 days.